New drug for advanced breast cancer: how does it affect daily life?
NCT ID NCT07563595
First seen May 09, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This study tracks about 500 postmenopausal women with a certain type of advanced breast cancer (ER+, HER2-, with an ESR1 mutation) who are taking the drug elacestrant. Researchers want to see how the drug affects quality of life, side effects, and how well it works in everyday medical practice. The goal is to understand real-world benefits and risks beyond what was seen in earlier clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gemeinschaftspraxis für Hämatologie und Onkologie
Ravensburg, 88212, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St. Louise Frauen- und Kinderklinik
Paderborn, 33098, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.